Physician profile
John P Schultz
NPI 1730176900
$799.72
in general payments reported to CMS, 2019-2025
15 companies · $59.54 in 2025
The $59.54 reported for 2025 was less than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $57.93 · 2021: $58.76 · 2022: $91.36 · 2023: $176 · 2024: $102 · 2025: $59.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $170.82 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $170.29 | 2019-2024 | Mounjaro |
| Allergan, INC. | $137.37 | 2019-2020 | |
| Glaxosmithkline, LLC. | $62.65 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $46.20 | 2022 | |
| Amarin Pharma, INC. | $30.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.45 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $27.30 | 2024 | Airsupra, Brilinta |
| Abbvie INC. | $26.06 | 2024 | |
| Alkermes, INC. | $23.16 | 2023 | Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $18.20 | 2019 | |
| Abbott Laboratories | $17.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.72 | 2021 | |
| Promius Pharma LLC | $13.45 | 2019 | |
| Indivior INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.